GPC3 and liver cancer: In addition to utilizing single-cell technology to identify new targeted antigens, such as Glypican-3 (GPC3), Alpha-fetoprotein (AFP), and EpCAM, CAR-T cell therapy has shown potential as a treatment option for liver cancer when combined with immune checkpoint inhibitors (Chen and E C-Y, Gong Z-W, Liu S, Wang Z-X, Yang Y-S, 2018; Makkouk et al. 2021).